Celcuity's Gedatolisib: Navigating the Path to Broad FDA Approval in Breast Cancer
Decision brief
Answer first · skim in under a minute
Celcuity has announced positive topline data from its Phase 3 VIKTORIA-1 trial for gedatolisib in breast cancer, positioning the company for a broad FDA filing. This development marks a significant catalyst for the company and the broader oncology landscape.
Gedatolisib enters mid-2026 FDA review with Priority Review, a July 17 PDUFA date, and VIKTORIA-1 wild-type data that reset expectations for post-CDK4/6 HR-positive breast cancer therapy.
Contents12 sections
Key Takeaways
- FDA accepted the NDA and assigned PDUFA July 17, 2026, under Priority Review and RTOR.
- VIKTORIA-1 wild-type triplet HR 0.24; doublet HR 0.33 versus fulvestrant.
- Median PFS: 9.3 months (triplet) and 7.4 months (doublet) versus 2.0 months control.
- A separate PIK3CA-mutant cohort readout is expected to shape any broader label strategy.
Where does gedatolisib stand with the FDA?
Celcuity announced FDA acceptance of its NDA with Priority Review and a July 17, 2026, PDUFA date in a January 20, 2026 GlobeNewswire release.
The application was submitted under the Real-Time Oncology Review program.
Gedatolisib previously received Breakthrough Therapy and Fast Track designations.
What did VIKTORIA-1 show in PIK3CA wild-type disease?
The Phase 3 study is registered as NCT05501886.
In the wild-type cohort, gedatolisib plus fulvestrant and palbociclib produced median PFS of 9.3 months versus 2.0 months with fulvestrant (HR 0.24).
Gedatolisib plus fulvestrant alone produced median PFS of 7.4 months versus 2.0 months (HR 0.33).
- Triplet median PFS: 9.3 months
- Doublet median PFS: 7.4 months
- Control median PFS: 2.0 months
Why does the wild-type population matter commercially?
PIK3CA wild-type HR+/HER2- disease after CDK4/6 inhibition has fewer approved targeted options than mutant disease.
A clean wild-type approval would open a large second-line segment before any mutant expansion.
Competitors in the PI3K/AKT/mTOR space will be judged against these hazard ratios.
What stands between today's NDA and a broader label?
The accepted NDA covers the wild-type cohort; mutant-cohort data are a separate regulatory path.
Celcuity has discussed a supplemental filing if mutant-cohort results are positive.
Safety watch items include stomatitis and hyperglycemia, though grade 3/4 hyperglycemia rates were described as lower than some isoform-specific PI3K inhibitors.
How should investors frame the July 17, 2026, PDUFA?
Priority Review plus RTOR shortens the clock but does not guarantee approval.
Absence of a publicly announced advisory committee meeting is a neutral-to-constructive signal, not a decision.
Compare the pathway with other recent breast oncology approvals tracked on FDA's approved-drugs resources.
What remains unproven before launch assumptions harden?
Overall survival maturity and real-world tolerability still need post-approval confirmation.
Broader use in PIK3CA-mutant disease is not established by the wild-type NDA alone.
Manufacturing scale-up and payer sequencing versus fulvestrant combinations will decide uptake speed.
How does gedatolisib's mechanism differ from isoform-specific PI3K drugs?
Gedatolisib is described as a pan-PI3K and mTORC1/2 inhibitor, a broader pathway blockade than several isoform-selective PI3K agents already used in mutant disease.
That breadth may help explain activity in PIK3CA wild-type tumors where isoform-selective drugs have been less compelling.
It also raises the usual hyperglycemia and mucosal toxicity watch items that clinics manage with prophylaxis and dose holds.
What commercial sequencing questions will payers ask first?
If approved, payers will ask whether the triplet or doublet is preferred and how to sequence versus fulvestrant combinations already on formularies.
They will also ask for biomarker confirmation workflows that prove wild-type status before high-cost initiation of gedatolisib.
A later mutant-cohort supplemental filing could expand volume but might also complicate prior-authorization logic.
Manufacturing readiness by the July 17, 2026, PDUFA date will decide whether an approval becomes a real launch.
Until July 17, 2026, gedatolisib remains a Priority Review story defined by wild-type VIKTORIA-1 hazard ratios and confirmatory manufacturing readiness.
Celcuity's July 17, 2026 PDUFA date is now the near-term catalyst; secondary focus stays on the PIK3CA mutant cohort timing after the wild-type NDA.
Related NovaPharma coverage
Frequently Asked Questions
What is the FDA status of gedatolisib?
FDA accepted Celcuity's NDA for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer, granted Priority Review, and set a PDUFA goal date of July 17, 2026.
What trial supports the gedatolisib NDA?
The filing is based on the PIK3CA wild-type cohort of Phase 3 VIKTORIA-1 (NCT05501886), which tested gedatolisib regimens versus fulvestrant after CDK4/6 inhibitor and aromatase inhibitor progression.
How strong were the VIKTORIA-1 progression-free survival results?
In reported wild-type cohort data, the gedatolisib triplet reduced risk of progression or death with a hazard ratio of 0.24 (median PFS 9.3 vs 2.0 months), and the doublet posted a hazard ratio of 0.33 (median PFS 7.4 vs 2.0 months).
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for gedatolisib.
Unlock full calendar →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only) — This policy outlines medically necessary radiation therapy protocols for conditions like breast canc…